Key Points
- Insider sale: Jeremy Hayden sold 44,850 shares on Nov. 25 at an average price of $8.08 for $362,388, trimming his position by 14.88% to 256,590 shares (≈$2.07M).
- Company snapshot: SGHT opened at $8.39 (near its 1‑year high of $8.47) but reported a quarterly loss of ($0.81) EPS, negative margins and ROE, a $443.6M market cap, and carries an average analyst rating of "Hold" with a $5.17 target.
Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) insider Jeremy Hayden sold 44,850 shares of Sight Sciences stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $8.08, for a total transaction of $362,388.00. Following the completion of the transaction, the insider directly owned 256,590 shares in the company, valued at approximately $2,073,247.20. The trade was a 14.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Sight Sciences Stock Up 3.6%
Shares of SGHT stock opened at $8.39 on Thursday. The stock's fifty day moving average price is $4.96 and its 200 day moving average price is $4.21. Sight Sciences, Inc. has a 1-year low of $2.03 and a 1-year high of $8.47. The company has a market cap of $443.58 million, a price-to-earnings ratio of -9.32 and a beta of 2.47. The company has a debt-to-equity ratio of 0.62, a current ratio of 9.60 and a quick ratio of 8.93.
Sight Sciences (NASDAQ:SGHT - Get Free Report) last posted its quarterly earnings results on Wednesday, September 8th. The company reported ($0.81) earnings per share (EPS) for the quarter. Sight Sciences had a negative return on equity of 61.59% and a negative net margin of 60.63%.The company had revenue of $12.54 million during the quarter. On average, research analysts expect that Sight Sciences, Inc. will post -0.99 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Sight Sciences
Several hedge funds and other institutional investors have recently made changes to their positions in SGHT. BNP Paribas Financial Markets boosted its stake in Sight Sciences by 99.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company's stock worth $26,000 after purchasing an additional 3,785 shares during the last quarter. CWM LLC lifted its stake in shares of Sight Sciences by 70.2% in the second quarter. CWM LLC now owns 7,607 shares of the company's stock worth $31,000 after buying an additional 3,137 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in Sight Sciences by 32.7% during the second quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company's stock worth $48,000 after acquiring an additional 2,875 shares during the last quarter. Bank of Montreal Can purchased a new stake in Sight Sciences during the 2nd quarter valued at about $49,000. Finally, Vanguard Personalized Indexing Management LLC raised its holdings in Sight Sciences by 38.9% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 15,888 shares of the company's stock valued at $66,000 after acquiring an additional 4,453 shares during the last quarter. Hedge funds and other institutional investors own 55.51% of the company's stock.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on SGHT. Needham & Company LLC reissued a "hold" rating on shares of Sight Sciences in a report on Thursday, August 28th. Piper Sandler increased their target price on shares of Sight Sciences from $4.00 to $5.00 and gave the stock a "neutral" rating in a research note on Friday, November 7th. Lake Street Capital lifted their price target on Sight Sciences from $5.00 to $7.00 and gave the company a "buy" rating in a research note on Tuesday, October 21st. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Sight Sciences in a report on Thursday, November 20th. Finally, Wall Street Zen upgraded Sight Sciences from a "sell" rating to a "hold" rating in a research report on Saturday, September 13th. Three investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Sight Sciences presently has an average rating of "Hold" and an average target price of $5.17.
Check Out Our Latest Stock Analysis on SGHT
Sight Sciences Company Profile
(
Get Free Report)
Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
